Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Enphase Energy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Enphase Energy Inc trades at $42.99 (market cap $5.67B). The key difference: Enphase Energy Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | ENPH | |
|---|---|---|
Market Cap | $4.49B | $5.67B |
Sector | Health | Technology |
52-Week High | $28.06 | $72.33 |
52-Week Low | $20.06 | $26.12 |
Enterprise Value | $3.69B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ENPH trades at $42.99, down 0.19% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 EPS of $0.47, beating expectations, but revenue declined to $1.47B in 2025 from $2.3B in 2023. Recent news highlights its entry into AI data center power standards and new product launches, including IQ9N microinverters.
Outlook is mixed: analyst consensus is a 'Hold' with a $41.61 price target, below the current price. Opportunities include expansion into AI-driven energy solutions, but risks involve revenue volatility, high valuation multiples, and competitive pressures in the solar sector. Net cash flow remains positive but has weakened from prior years.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
